Department of Surgery, Division of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Mol Imaging. 2011 Aug;10(4):248-57. doi: 10.2310/7290.2011.00004. Epub 2011 Apr 26.
Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of research that is on the verge of clinical implementation. As each tumor has its unique biologic profile, selection of the most promising targets is essential. In this review, we focus on target finding in ovarian cancer, a disease in which fluorescence imaging may be of value in both adequate staging and in improving cytoreductive efforts, and as such may have a beneficial effect on prognosis. Thus far, tumor-targeted imaging for ovarian cancer has been applied only in animal models. For clinical implementation, the five most prominent targets were identified: folate receptor α, vascular endothelial growth factor, epidermal growth factor receptor, chemokine receptor 4, and matrix metalloproteinase. These targets were selected based on expression rates in ovarian cancer, availability of an antibody or substrate aimed at the target approved by the Food and Drug Administration, and the likelihood of translation to human use. The purpose of this review is to present requirements for intraoperative imaging and to discuss possible tumor-specific targets for ovarian cancer, prioritizing for targets with substrates ready for introduction into the clinic.
肿瘤靶向荧光成像是癌症诊断和治疗中一个不断发展的研究领域，即将进入临床应用。由于每个肿瘤都有其独特的生物学特征，因此选择最有前途的靶点至关重要。在这篇综述中，我们专注于卵巢癌的靶点发现，荧光成像在充分分期和提高细胞减灭术方面可能具有价值，从而可能对预后产生有益影响。到目前为止，卵巢癌的肿瘤靶向成像仅在动物模型中应用。为了临床应用，确定了五个最突出的靶点：叶酸受体 α、血管内皮生长因子、表皮生长因子受体、趋化因子受体 4 和基质金属蛋白酶。这些靶点是根据卵巢癌中的表达率、针对已获美国食品和药物管理局批准的靶点的抗体或底物的可用性以及转化为人类使用的可能性选择的。本文的目的是介绍术中成像的要求，并讨论卵巢癌的可能肿瘤特异性靶点，优先考虑具有可引入临床的底物的靶点。
